{"entity":{"id":"nct05844150","kind":"trial","name":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC","aka":[],"tldr":"A phase 2 trial of PM8002 and Etoposide in small-cell lung cancer, run by Biotheus Inc., active and no longer recruiting.","summary":"A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC is a phase 2 interventional study registered as NCT05844150 by Biotheus Inc., with 50 participants enrolled, started 2023-06-01 and due to reach its primary completion in 2024-05-10. Interventions recorded: PM8002, Platinum and Etoposide.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05844150","url":"https://clinicaltrials.gov/study/NCT05844150"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pm8002","etoposide"],"companies":["biontech"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05844150","phase":"2","setting":"A Phase II Clinical Trial to Evaluate the Efficacy and Safety of PM8002 in Combination With Etoposide and Platinum in First-line Treatment of Extensive-Stage Small Cell Lung Cancer","sponsor":"Biotheus Inc.","enrolled":50,"outcomes":[]},"route":"/trials/nct05844150/","neighbours":{"cancer":[{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"etoposide","kind":"drug","name":"Etoposide","route":"/drugs/etoposide/"},{"id":"pm8002","kind":"drug","name":"PM8002","route":"/drugs/pm8002/"}],"company":[{"id":"biontech","kind":"company","name":"BioNTech","route":"/companies/biontech/"}]}}